Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medication for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5mg and metformin hydrochloride extended-release 2000 mg.
This medication should be taken once daily with a meal, preferably with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually.
To maintain its extended-release properties, this medication should be swallowed whole and not split, crushed, ground, or chewed.
The 5/1000 mg extended-release tablet of this medication should be taken once daily as 1 tablet per dose.
Patients taking the 2.5/1000 mg extended-release tablets of this medication should take 2 tablets together once daily.
1. Patients not currently receiving metformin:
The initial dose of this medication is a total daily dose of linagliptin 5 mg and metformin hydrochloride 1000mg. The dose of metformin hydrochloride may be gradually increased up to the maximum recommended daily dose of 2000 mg.
2. Patients receiving metformin
- For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this medication is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride.
- For patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, or metformin and insulin, an initial dose of this medication consisting of a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's current dose should be considered. When this medication is administered concomitantly with insulin or a sulfonylurea, a reduction in the dose of insulin or the sulfonylurea may be necessary to reduce the risk of hypoglycemia.
- When switching from an immediate-release metformin formulation to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted appropriately if necessary.
- When switching from combination therapy with linagliptin and extended-release metformin to this medication, the dose of this medication is the patient's current dose of linagliptin and extended-release metformin hydrochloride.
Renal impairment
Because dose adjustment according to renal function is necessary, assessment of renal function is recommended before starting this medication and periodically during treatment.
No dose adjustment of this medication is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2].
In patients with moderate renal impairment (CKD stage 3A), with creatinine clearance (CrCl) of 45mL/min or more and less than 60mL/min, or estimated glomerular filtration rate (eGFR) of 45mL/min/1.73m2 or more and less than 60mL/min/1.73m2, who tolerate treatment well and have no other conditions that may increase the risk of lactic acidosis, this medication may be used with adjustment of the metformin hydrochloride dose as follows.
The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this medication. The maximum daily dose of metformin hydrochloride is 1000mg.
If creatinine clearance (CrCl) falls below 45mL/min or estimated glomerular filtration rate (eGFR) falls below 45mL/min/1.73m2, this medication should be discontinued immediately.
Improvement of glycemic control in patients with type 2 diabetes mellitus
View approved original textHide original text
This medication is used to assist patients with type 2 diabetes in effectively controlling their blood sugar levels. Linagliptin and Metformin work together to provide help for blood sugar management that is insufficient with dietary and exercise therapy alone. With consistent intake, it improves blood sugar levels and contributes to reducing the risk of complications, playing a significant role in patients' healthy blood sugar regulation.
How to take
Adult dose
The dose of this medication for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5mg and metformin hydrochloride extended-release 2000 mg.
This medication should be taken once daily with a meal, preferably with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually.
To maintain its extended-release properties, this medication should be swallowed whole and not split, crushed, ground, or chewed.
The 5/1000 mg extended-release tablet of this medication should be taken once daily as 1 tablet per dose.
Patients taking the 2.5/1000 mg extended-release tablets of this medication should take 2 tablets together once daily.
1. Patients not currently receiving metformin:
The initial dose of this medication is a total daily dose of linagliptin 5 mg and metformin hydrochloride 1000mg. The dose of metformin hydrochloride may be gradually increased up to the maximum recommended daily dose of 2000 mg.
2. Patients receiving metformin
- For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this medication is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride.
- For patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, or metformin and insulin, an initial dose of this medication consisting of a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's current dose should be considered. When this medication is administered concomitantly with insulin or a sulfonylurea, a reduction in the dose of insulin or the sulfonylurea may be necessary to reduce the risk of hypoglycemia.
- When switching from an immediate-release metformin formulation to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted appropriately if necessary.
- When switching from combination therapy with linagliptin and extended-release metformin to this medication, the dose of this medication is the patient's current dose of linagliptin and extended-release metformin hydrochloride.
Renal impairment
Because dose adjustment according to renal function is necessary, assessment of renal function is recommended before starting this medication and periodically during treatment.
No dose adjustment of this medication is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2].
In patients with moderate renal impairment (CKD stage 3A), with creatinine clearance (CrCl) of 45mL/min or more and less than 60mL/min, or estimated glomerular filtration rate (eGFR) of 45mL/min/1.73m2 or more and less than 60mL/min/1.73m2, who tolerate treatment well and have no other conditions that may increase the risk of lactic acidosis, this medication may be used with adjustment of the metformin hydrochloride dose as follows.
The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this medication. The maximum daily dose of metformin hydrochloride is 1000mg.
If creatinine clearance (CrCl) falls below 45mL/min or estimated glomerular filtration rate (eGFR) falls below 45mL/min/1.73m2, this medication should be discontinued immediately.
Precautions
This medication is used for controlling blood sugar and is primarily prescribed to diabetes patients.
It should not be used in certain patients. For example, it should not be administered to those allergic to any of its ingredients or those with type 1 diabetes, severe renal impairment, hepatic impairment, acute alcohol intoxication, or severe heart disease.
Although rare, this medication can cause a serious condition called lactic acidosis, which can be life-threatening, so caution is necessary. The risk of lactic acidosis is higher when there is compromised renal function or other severe conditions such as infections, dehydration, or heart disease.
During the course of this medication, symptoms of hypoglycemia may occur, especially when taken together with insulin or sulfonylureas; therefore, blood sugar levels should be monitored carefully.
Elderly patients or those taking other medications that may affect renal function should have their kidney function tested before taking this medication, and kidney status should be checked regularly.
If iodine contrast agents are used during acute surgical procedures or radiological exams, this medication should be temporarily discontinued, and it should be resumed only after normal kidney function is restored following the exam.
This medication should be swallowed whole and not chewed or crushed, and it is normal for tablet shells to be expelled in the stool.
If severe abdominal pain, persistent vomiting, muscle weakness, or difficulty breathing occur during treatment, immediate consultation with a physician is necessary.
This medication is not recommended for use in pregnant or breastfeeding women, and consultation with a physician is advised if pregnancy is planned.
Alcohol consumption should be avoided during this medication, as it may increase the risk of side effects associated with the drug.
This medication can interact with other drugs, so it is essential to inform the physician of all medications currently being taken, especially those that may affect renal function, before use.
In case of an overdose, immediate medical attention should be sought for appropriate treatment, especially if lactic acidosis is suspected.
Side effects
Severe lactic acidosis
hypoglycemia
nasopharyngitis
hypersensitivity reactions
angioedema
urticaria
lactic acidosis
abnormal vitamin B12 absorption test
hypoglycemic episodes
taste disturbance
Show 131 moreCollapse
cough
decreased appetite
diarrhea
constipation
nausea
pancreatitis
vomiting
abdominal pain
oral ulcer
abnormal liver function tests
hepatitis
pruritus
erythema
rash
dermatitis herpetiformis
severe and disabling arthralgia
rhabdomyolysis
increased lipase
increased amylase
constipation
epigastric pain
enterocolitis
bowel obstruction
gastroenteritis
herpes zoster
cystitis
acute pyelonephritis
bronchitis
vestibular neuronitis
sepsis
pneumonia
decreased appetite
dehydration
hyperglycemia
cerebral infarction
stuttering
Alzheimer's-type dementia
chest pain
fever
facial edema
fatigue
chronic obstructive pulmonary disease
asthma
skin lesions
liver metastasis
acute leukemia
basal cell carcinoma
non-small cell lung cancer
malignant pericardial effusion
gastric cancer
rectal cancer
pancreatic cancer
meniscal injury
pneumoconiosis
congestive heart failure
angina
acute myocardial infarction
unstable angina
cardiac arrest
diabetic retinopathy
acute kidney injury
end-stage renal disease
acute cholangitis
acute cholecystitis
cholangitis
dizziness
kidney transplant failure
stomatitis
mediastinitis
vitreous hemorrhage
fever
ligament sprain
flank pain
myelodysplastic syndrome
vocal cord polyp
dyspepsia
rectal bleeding
cheilitis
dental caries
enteritis
gastritis
stomatitis
dizziness
headache
drowsiness
chest discomfort
myasthenia
epistaxis
oropharyngeal pain
voice disorder
allergic rhinitis
exertional dyspnea
wet cough
runny nose
pulmonary mass
arthralgia
osteoporosis
arthropathy
musculoskeletal discomfort
myositis
myalgia
soft tissue mass
postmenopausal osteoporosis
rotator cuff syndrome
increased serum triglycerides
increased urine albumin/creatinine ratio
positive urine leukocytes
decreased hemoglobin
increased serum potassium
increased serum creatinine
increased serum creatine phosphokinase
increased ALT
male pattern baldness
hyperhidrosis
dermatitis
anxiety
mood disorder
insomnia
depression
contusion
bone contusion
concussion
bone fracture
hand fracture
altered mental status
nocturia
dermatitis
hypertension
benign prostatic hyperplasia
goiter
erectile dysfunction
Not everyone experiences these, and they can vary from person to person.
Storage
This medication is sensitive to air and moisture; therefore, it should be stored in a tightly sealed container. It is best to maintain storage temperatures between 1 and 30 degrees Celsius.
Appearance and packaging
Appearance
Oval extended-release tablet, white to almost white, engraved with LK5 on one side
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
Questions about this medicine
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety. Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.